Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 15 Lymphoid 15 Myeloid 13 Plasma cell 4 Classical hematology 4 Genitourinary 2 Gastrointestinal 2 Dermatologic 2 Breast 2 Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 CNS 1

Conditions

Thymoma 1 Thymic epithelial tumor 1

Interventions

Carboplatin 1152 Cisplatin 876 Pemetrexed 834 pembrolizumab 608 Paclitaxel 598 Docetaxel 535 Gemcitabine 424 Radiotherapy 377 Erlotinib Hydrochloride 367 Nivolumab 322 Bevacizumab 322 Etoposide 295 durvalumab 254 Drug Therapy 233 osimertinib 218 atezolizumab 208 Radiosurgery 190 Gefitinib 177 Vinorelbine 145 130-nm albumin-bound paclitaxel 124 Magnetic Resonance Spectroscopy 121 Ipilimumab 118 Cetuximab 113 anlotinib 104 tislelizumab 103 Topotecan 101 Cyclophosphamide 101 Taxes 99 Irinotecan 95 Albumin-Bound Paclitaxel 92

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × AP 1903 reagent × Thoracic × Clear all

NCT07598955 2026-05-20

SELECT-NK-THYM

Beijing Biotech

Phase 1/2 Recruiting

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡